

## Recombinant Human CD153/CD30L/TNFSF8 Protein

**Catalog No.** PKSH030309

**Note:** Centrifuge before opening to ensure complete recovery of vial contents.


### Description

|                                    |                            |
|------------------------------------|----------------------------|
| <b>Synonyms</b>                    | CD153;CD30L;CD30LG         |
| <b>Species</b>                     | Human                      |
| <b>Expression Host</b>             | HEK293 Cells               |
| <b>Sequence</b>                    | Gln 63-Asp 234             |
| <b>Accession</b>                   | NP_001235.1                |
| <b>Calculated Molecular Weight</b> | 19.6 kDa                   |
| <b>Tag</b>                         | None                       |
| <b>Bioactivity</b>                 | Not validated for activity |

### Properties

|                       |   |
|-----------------------|---|
| <b>Purity</b>         | > 90 % as determined by reducing SDS-PAGE.  |
| <b>Endotoxin</b>      | < 1.0 EU per µg of the protein as determined by the LAL method.   |
| <b>Storage</b>        | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months. |
| <b>Shipping</b>       | This product is provided as lyophilized powder which is shipped with ice packs.   |
| <b>Formulation</b>    | Lyophilized from sterile PBS, pH 7.4<br>Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.<br>Please refer to the specific buffer information in the printed manual.            |
| <b>Reconstitution</b> | Please refer to the printed manual for detailed information.  |

### Data



> 90 % as determined by reducing SDS-PAGE.

### Background

CD30 ligand (CD30L), also known as CD153 and TNFSF8, is a membrane-associated glycoprotein belonging to the TNF superfamily and TNFR superfamily, and is a specific ligand for CD30/TNFRSF8 originally described as a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. CD30L is a type-II membrane

### For Research Use Only

glycoprotein expressed on activated T cells, stimulated monocyte-macrophages, granulocytes, eosinophils, and some Burkitt-like lymphoma cell lines. CD30L is capable of transducing signals through CD30 on different CD30+ lymphoma cell lines, and mediates pleiotropic biologic effects including cell proliferation, activation, differentiation, as well as cell death by apoptosis. CD30-CD30 ligand interaction has been suggested to have a pathophysiologic role in malignant lymphomas, particularly Hodgkin disease, large cell anaplastic lymphomas and Burkitt lymphomas, and is also involved in activation and functioning of the T cell-dependent immune response. Thus, CD153 and its receptor CD30 are regarded as therapeutic targets in hematologic malignancies, autoimmune and inflammatory diseases.